Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following…
KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026
RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe…
Phase 3 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
June 13, 2026 16:00 ET | Source: Ascendis Pharma Multi-organ system and…
FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know
New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's…
Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance
BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong…
Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000
MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning…
Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City
MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies…
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful…
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
June 13, 2026 07:30 ET | Source: Intellia Therapeutics, Inc. Data from…
New TALVEY(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and…
